Literature DB >> 2426276

Acute leukemia in a patient cured of diffuse histiocytic lymphoma.

J P Dutcher, P H Wiernik.   

Abstract

A patient is described who, after completing treatment for diffuse histiocytic lymphoma, remained disease-free for 7 years (presumably cured), then developed acute nonlymphocytic leukemia (ANLL) after a brief preleukemic phase. Marrow cytogenetic analysis at the onset of frank leukemia revealed loss of chromosomes 5 and 7, which is consistent with secondary leukemia. She received only chemotherapy for her lymphoma, including high doses of an alkylating agent and a nitrosourea, which may have contributed to the development of the leukemia. This case report suggests that secondary ANLL may complicate the course of some long-term disease-free survivors of diffuse histiocytic lymphoma.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2426276     DOI: 10.1007/bf00394942

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  39 in total

1.  Recticulum cell sarcoma terminating in acute leukemia.

Authors:  J L ZEFFREN; J E ULTMANN
Journal:  Blood       Date:  1960-02       Impact factor: 22.113

2.  Transformation of reticulum cell sarcoma to acute leukemia.

Authors:  S Lowenbraun; J C Sutherland; M J Feldman; A A Serpick
Journal:  Cancer       Date:  1971-03       Impact factor: 6.860

3.  [Appearance of acute myeloid leukemia during the development of lymphosarcoma].

Authors:  G Gosselin; J Neemeh; L A Long; H Pretty; R Lefebvre
Journal:  Union Med Can       Date:  1970-05

4.  Advanced diffuse histiocytic lymphoma, a potentially curable disease.

Authors:  V T DeVita; G P Canellos; B Chabner; P Schein; S P Hubbard; R C Young
Journal:  Lancet       Date:  1975-02-01       Impact factor: 79.321

5.  Incidence of acute nonlymphocytic leukemia, preleukemia, and acute myeloproliferative syndrome up to 10 years after treatment of Hodgkin's disease.

Authors:  J Pedersen-Bjergaard; S O Larsen
Journal:  N Engl J Med       Date:  1982-10-14       Impact factor: 91.245

6.  Prognostic factors for advanced diffuse histiocytic lymphoma following treatment with combination chemotherapy.

Authors:  R I Fisher; V T DeVita; B L Johnson; R Simon; R C Young
Journal:  Am J Med       Date:  1977-08       Impact factor: 4.965

7.  Coexistent lymphosarcoma and chronic granulocytic leukemia.

Authors:  B D Wilson; E J VanSlyck
Journal:  Cancer       Date:  1966-06       Impact factor: 6.860

8.  Comparison of intensive versus moderate chemotherapy of lymphocytic lymphomas: a progress report.

Authors:  E Ezdinli; S Pocock; C W Berard; C W Aungst; M Silverstein; J Horton; J Bennett; R Bakemeier; L Stolbach; C Perlia; S F Brunk; R E Lenhard; D J Klaassen; P Richter; P Carbone
Journal:  Cancer       Date:  1976-09       Impact factor: 6.860

9.  Acute nonlymphocytic leukemia associated with nitrosourea chemotherapy: report of two cases.

Authors:  R J Cohen; P H Wiernik; M D Walker
Journal:  Cancer Treat Rep       Date:  1976-09

10.  Bleomycin, adriamycin, cyclophosphamide, vincristine, and prednisone (BACOP) combination chemotherapy in the treatment of advanced diffuse histiocytic lymphoma.

Authors:  P S Schein; V T DeVita; S Hubbard; B A Chabner; G P Canellos; C Berard; R C Young
Journal:  Ann Intern Med       Date:  1976-10       Impact factor: 25.391

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.